Abbott Laboratories discovers, develops, manufactures and sells a broad and diversified line of health care products and services. The company’s products include pharmaceuticals, nutritional, diagnostic, and vascular products.

The 2011 annual report shows a net sales’ increase of 10% nearly $38 million and a net earnings at $4.73 million, up 2% against one year previous. More than 55% of its revenues come from pharmaceutical division. The largest selling-drug is Humira, which treats rheumatoid arthritis and other conditions, rose 21% in 2011.

Technically, after several bullish trading sessions the share is testing the $ 60.5 long-term resistance. This level is an important psychological threshold tested two times in 2007 and 2008, and over which the share is never passed. We could imagine in the next few sessions a technical correction towards $57, converging point between short-term support and 20-periods moving average. We suggest a stop loss above the resistance at $61, in order to cover the position.